Curated News
By: NewsRamp Editorial Staff
September 04, 2025
Soligenix's ThermoVax Ebolavirus Vaccines Show 2-Year Stability at 40°C
TLDR
- Soligenix's ThermoVax platform gives a strategic edge by enabling stable ebolavirus vaccines without cold-chain, reducing costs and boosting distribution efficiency in pandemic response.
- Soligenix's ThermoVax technology stabilizes protein subunit vaccines at up to 40°C for two years, using heat-resistant formulation to maintain potency and simplify storage logistics.
- Soligenix's thermostable vaccines improve global health equity by enabling reliable distribution to remote areas, enhancing pandemic preparedness and saving lives in underserved communities.
- Soligenix's ebolavirus vaccines achieve 100% protection in primates and remain potent after two years at high temperatures, a breakthrough in vaccine stability science.
Impact - Why it Matters
This development matters because thermostable vaccines eliminate the need for cold-chain storage, which is a major barrier to vaccine distribution in remote or resource-limited areas. By maintaining potency at high temperatures, these vaccines could drastically improve access to life-saving immunizations during outbreaks of deadly viruses like Ebola and Marburg, enhancing global pandemic preparedness and potentially saving countless lives in regions where refrigeration is unreliable or unavailable.
Summary
Soligenix Inc., a late-stage biopharmaceutical company focused on rare diseases, has announced groundbreaking data showing that its ebolavirus vaccines developed with the proprietary ThermoVax platform maintain full potency after two years of storage at temperatures up to 40°C (104°F). The bivalent and trivalent vaccines, formulated from Zaire ebolavirus, Sudan ebolavirus, and Marburg marburgvirus antigens, demonstrated robust immune responses in animal models with up to 100% protection in non-human primates. This development, achieved in collaboration with Dr. Axel Lehrer at the University of Hawaiʻi at Mānoa, represents a significant advancement in vaccine technology by eliminating cold-chain requirements, which could revolutionize global vaccine distribution and pandemic preparedness.
The company's Public Health Solutions business segment, which includes these vaccine programs, has been supported by government funding from agencies such as the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA). Soligenix's ThermoVax platform enhances protein subunit vaccines—considered the gold standard for safety—by making them thermostable, addressing critical logistical challenges in vaccine deployment. For more details, readers can view the full press release at https://ibn.fm/kh3GE, and additional updates are available in the company's newsroom at https://ibn.fm/SNGX.
Beyond its ebolavirus vaccines, Soligenix is also developing other innovative therapies, including HyBryte™ for cutaneous T-cell lymphoma and vaccine candidates for ricin toxin and COVID-19 (CiVax™). The company's work in rare diseases and public health solutions highlights its commitment to addressing unmet medical needs through cutting-edge science. This announcement underscores the potential for thermostable vaccines to improve accessibility and efficacy in combating infectious diseases worldwide, making it a pivotal moment for both the company and global health initiatives.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix's ThermoVax Ebolavirus Vaccines Show 2-Year Stability at 40°C
